Increasing enrollment of African Americans in early phase cancer trials
Randomized Trial of Recruitment Strategies for Early Phase Therapeutic Cancer Trials
This study is trying different ways to encourage more African Americans to join early cancer treatment trials to see if these methods can help increase participation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05886764 on ClinicalTrials.gov |
What this trial studies
This trial investigates various outreach methods aimed at enhancing the enrollment of underrepresented minorities, particularly African Americans, in early phase cancer clinical treatment trials. The study will involve both patients and their oncology providers, who will either receive the interventions or be placed in a control group without intervention. The focus is on assessing the effectiveness of digital outreach and community engagement strategies to improve participation rates in these critical trials.
Who should consider this trial
Good fit: Ideal candidates include African American individuals aged 18 and older who are scheduled for oncology appointments at the study site.
Not a fit: Patients with severe renal impairment or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly increase the representation of African Americans in early phase cancer trials, leading to more equitable treatment options.
How similar studies have performed: While outreach methods for increasing trial enrollment have been explored, this specific focus on African American populations in early phase cancer trials is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for Patient Subjects: * Aged 18 years or older * Self-described African American race (patients who self-describe as "more than one race" will be included) * Scheduled for new or consult oncology appointment at the study site * Scheduled for return outpatient oncology appointment at the study site with a biopsy or radiology encounter within 2 weeks prior to provider visit. * for prostate cancer patients: 2 or more increasing prostate specific antigen (PSA) values i the 6 months prior to visit * other patient identified by research team as potentially having a change in treatment prior to next outpatient oncology appointment at the study site Inclusion Criteria for Provider Subjects: * oncology provider at study site scheduled to see patients meeting criteria above Exclusion Criteria for Patient Subjects: * Estimated glomerular filtration rate (GFR) less than 30 ml/min/1.73m2 documented within last 2 months and without documented resolutions * Bilirubin greater than 3.0 ng/dl documented within last 2 months and without documented resolution * Initiated new anti-cancer therapy within last 2 months * Evaluated for possible enrollment/randomization in the last 2 months * Prior enrollment/randomization on this recruitment trial
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Walter Stadler — University of Chicago
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.